On Tuesday Roche presented positive Phase III results for the combination of its immunotherapy Tecentriq and lurbinectedin, a drug that prevents cancer cells from growing, in the treatment of advanced small cell lung cancer (SCLC).

The Swiss pharmaceutical group said that this combination reduced the risk of disease progression or death by 46% and the risk of death by 27% compared to Tecentriq alone as maintenance therapy.

SCLC is a particularly aggressive form of lung cancer, with the majority of patients diagnosed at an advanced stage and only one in five surviving beyond two years.

These data were presented in an oral session at the 2025 annual meeting of the American Society of Clinical Oncology (ASCO) and published simultaneously in the medical journal The Lancet.

On the Zurich Stock Exchange, Roche shares rose 0.5% on Tuesday morning following this announcement.


Copyright (c) 2025 CercleFinance.com. All rights reserved.